Management ChangeMay 22, 2026, 05:02 PM
Coeptis Therapeutics Co-CEO Michelle Burke Resigns; David Halabu Becomes Sole CEO
AI Summary
Coeptis Therapeutics Holdings, Inc. announced that Michelle Burke resigned as Co-Chief Executive Officer and director, effective May 22, 2026. Her resignation was not due to any disagreement with the company. Following her departure, David Halabu, who previously served as Co-CEO alongside Ms. Burke, will continue as the sole Chief Executive Officer of the company. Mr. Halabu's compensation arrangements remain unchanged.
Key Highlights
- Michelle Burke resigned as Co-Chief Executive Officer and director of Coeptis Therapeutics, effective May 22, 2026.
- Her resignation was not due to any disagreement with the company's operations, policies, or practices.
- Ms. Burke will be returning to Minting Dome, Inc., with the existing Master Services Agreement remaining in effect.
- David Halabu transitioned from Co-Chief Executive Officer to sole Chief Executive Officer, effective May 22, 2026.
- Mr. Halabu has served as Co-CEO since April 24, 2026, and CEO of Z Squared OpCo Inc. since June 2024.
- No changes were made to Mr. Halabu's compensation arrangements with the company.